Your browser doesn't support javascript.
loading
Frequency of anticancer drug use at the end of life: a scoping review
Szigethy, Endre; Dorantes, Rosario; Sugrañes, Miguel; Madera, Meisser; Sola, Ivan; Urrútia, Gerard; Bonfill, Xavier; Szigethy, Endre.
Affiliation
  • Szigethy, Endre; Universitat Autònoma de Barcelona. PhD Programme in Biomedical Research Methodology and Public Health. Barcelona. Spain
  • Dorantes, Rosario; Parc de Salut Mar. Centre Assistencial Dr. Emili Mira. Barcelona. Spain
  • Sugrañes, Miguel; Universitat Autònoma de Barcelona. School of Medicine. Barcelona. Spain
  • Madera, Meisser; University of Cartagena. Faculty of Dentistry. Research Department. Cartagena. Colombia
  • Sola, Ivan; Universitat Autònoma de Barcelona. CIBER Epidemiología y Salud Pública (CIBERESP). Biomedical Research Institute Sant Pau (IIB Sant Pau). Barcelona. Spain
  • Urrútia, Gerard; Universitat Autònoma de Barcelona. CIBER Epidemiología y Salud Pública (CIBERESP). Biomedical Research Institute Sant Pau (IIB Sant Pau). Barcelona. Spain
  • Bonfill, Xavier; Universitat Autònoma de Barcelona. CIBER Epidemiología y Salud Pública (CIBERESP). Biomedical Research Institute Sant Pau (IIB Sant Pau). Barcelona. Spain
  • Szigethy, Endre; Epidy Kft. Debrecen. Hungary
Clin. transl. oncol. (Print) ; 26(1): 178-189, jan. 2024.
Article in En | IBECS | ID: ibc-229156
Responsible library: ES1.1
Localization: ES15.1 - BNCS
ABSTRACT
Purpose Anticancer drug use at the end of life places potential extra burdens on patients and the healthcare system. Previous articles show variability in methods and outcomes; thus, their results are not directly comparable. This scoping review describes the methods and extent of anticancer drug use at end of life. Methods Systematic searches in Medline and Embase were conducted to identify articles reporting anticancer drug use at the end of life. Results We selected 341 eligible publications, identifying key study features including timing of research, disease status, treatment schedule, treatment type, and treatment characteristics. Among the subset of 69 articles of all cancer types published within the last 5 years, we examined the frequency of anticancer drug use across various end of life periods. Conclusion This comprehensive description of publications on anticancer drug use at end of life underscores the importance of methodological factors when designing studies and comparing outcomes (AU)
Subject(s)
Key words

Full text: 1 Collection: 06-national / ES Database: IBECS Main subject: Hospice Care / Terminally Ill / Neoplasms / Antineoplastic Agents Limits: Humans Language: En Journal: Clin. transl. oncol. (Print) Year: 2024 Document type: Article

Full text: 1 Collection: 06-national / ES Database: IBECS Main subject: Hospice Care / Terminally Ill / Neoplasms / Antineoplastic Agents Limits: Humans Language: En Journal: Clin. transl. oncol. (Print) Year: 2024 Document type: Article